InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the ” CGRP Inhibitor Market– (By Treatment (Preventive, Acute), By Route of Administration (Oral, Nasal, Intravenous), By End-User (Hospitals, Pharmacies, Specialty Clinics)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034.”
According to the latest research by InsightAce Analytic, the CGRP Inhibitor Market is valued at USD 3.3 Bn in 2024, and it is expected to reach USD 8.5 Bn by the year 2034, with a CAGR of 10.2% during the forecast period of 2025-2034.
Check this Report Brochure : https://www.insightaceanalytic.com/request-sample/2984
Calcitonin Gene-Related Peptide (CGRP) inhibitors constitute an innovative class of therapeutics specifically designed for the prevention and treatment of migraine headaches. CGRP, a neuropeptide integral to pain signaling and cerebral vasodilation, is a critical factor in the pathophysiology of migraines. These inhibitors act by targeting either the CGRP molecule or its receptor, effectively decreasing the frequency, intensity, and duration of migraine attacks.
Migraines impose significant physical distress and present a considerable economic burden due to productivity losses and absenteeism. The development of CGRP inhibitors has been supported by substantial research and development investments from leading pharmaceutical companies. These therapies have demonstrated notable clinical efficacy, marking a significant advancement in migraine management and addressing a crucial unmet need within the field of neurological care.
List of Prominent Players in the CGRP Inhibitor Market:
- Eli Lilly and Company
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd
- AbbVie Inc.
- Amgen Inc
- Novartis AG
- Allergan
- Biohaven Pharmaceutical Holding Company Ltd.
- Sun Pharmaceutical Industries Ltd
- Lundbeck
- AstraZeneca plc
- HoffmannLa Roche Ltd
- BristolMyers Squibb Company
- Other Market Players
Market Dynamics
Drivers:
The increasing global incidence of complex migraines and severe headache disorders is a primary factor propelling the demand for Calcitonin Gene-Related Peptide (CGRP) inhibitors. Migraines, often characterized by sensory hypersensitivity, nausea, and vomiting, represent a significant public health challenge due to their debilitating impact. In response to the considerable unmet medical need and the associated market opportunity, pharmaceutical companies are escalating research and development initiatives aimed at delivering innovative CGRP inhibitor therapies.
Challenges:
Despite demonstrated clinical efficacy, the high cost of CGRP inhibitors poses a considerable barrier, particularly in low- and middle-income regions where affordability and accessibility remain constrained. This financial burden on both patients and healthcare systems may limit broader adoption. Furthermore, the potential development of resistance to CGRP inhibitors could compromise their long-term effectiveness, highlighting the necessity for alternative therapeutic strategies. Overcoming these challenges is critical to sustaining market growth and expanding patient access to these advanced treatments.
Regional Trends:
North America is anticipated to maintain its leading position in the CGRP inhibitor market by revenue, supported by a robust compound annual growth rate (CAGR) over the forecast period. This growth is driven by the region’s well-established healthcare infrastructure, substantial investment in research and development, and the presence of prominent pharmaceutical companies and research institutions. Additionally, the high prevalence of migraine-related conditions in North America reinforces demand for effective therapeutic solutions, solidifying the region’s dominance in the CGRP inhibitor market.
Recent Developments:
- In March 2023, Pfizer Inc. announced that the U.S. FDA has approved ZAVZPRET (zavegepant), the inaugural and exclusive calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute management of migraine, with or without aura, in adults. In its crucial Phase 3 trial, ZAVZPRET demonstrated statistical superiority over placebo regarding the co-primary goals of pain relief and alleviation of the most bothersome symptom at two hours post-administration. The crucial study also exhibited pain alleviation as soon as 15 minutes in a predetermined secondary goal compared to placebo.
Segmentation of CGRP Inhibitor Market-
By Treatment-
- Preventive
- Acute
By Route of Administration-
- Oral
- Nasal
- Intravenous
By End-User-
- Hospitals
- Pharmacies
- Specialty Clinics
By Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
